Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Total Liabilities: 2023-2025

Historic Total Liabilities for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $140.6 million.

  • Inhibrx Biosciences' Total Liabilities rose 218.95% to $140.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.6 million, marking a year-over-year increase of 218.95%. This contributed to the annual value of $47.2 million for FY2024, which is 82.15% down from last year.
  • As of Q3 2025, Inhibrx Biosciences' Total Liabilities stood at $140.6 million, which was down 2.03% from $143.6 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Total Liabilities registered a high of $264.4 million during Q4 2023, and its lowest value of $39.1 million during Q2 2024.
  • Moreover, its 3-year median value for Total Liabilities was $140.6 million (2025), whereas its average is $118.2 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 82.15% in 2024, then surged by 267.61% in 2025.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' Total Liabilities stood at $264.4 million in 2023, then slumped by 82.15% to $47.2 million in 2024, then spiked by 218.95% to $140.6 million in 2025.
  • Its Total Liabilities was $140.6 million in Q3 2025, compared to $143.6 million in Q2 2025 and $148.2 million in Q1 2025.